Rgenix
310 East 67th Street, Suite 1-12?
New York
New York
10065
United States
Tel: 646-856-9261
Website: http://www.rgenix.com/
Email: info@rgenix.com
23 articles with Rgenix
-
RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting
6/22/2020
RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-019, RGENIX’s pre-clinical antibody program in development. RGENIX’s abstract, “In Vivo Safety and Efficacy of RGX-019, a MerTK Targeting Monoclonal Antibody” was accepted for the 2020 American Association for Cancer Research (AACR) Annual Meeting
-
RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting
6/22/2020
RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors”
-
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
Clinical Catch-Up: May 25-29
6/1/2020
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look. -
RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial
5/29/2020
RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting data showing clinical activity in patients with advanced colorectal (CRC) tumors from a clinical trial of RGX-202, a first-in-class small molecule that inhibits a novel canc
-
In the midst of a pandemic, oncology-focused companies virtually unveil data at the American Association for Cancer Research (AACR) Annual Meeting.
-
RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting
4/27/2020
RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR); Initial results from the phase 1b RGX-104 plus Docetaxel combination dose escalation cohorts” was accepte
-
Rgenix Names Industry Veteran to Chief Medical Officer Role
9/16/2019
Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles in the biopharma industry
-
Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
4/3/2019
Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting pre-clinical data from ongoing research of RGX-019,
-
Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting
4/1/2019
Rgenix, Inc. announced that Isabel Kurth, Ph.D., Vice President of Research at Rgenix, will present an abstract about Rgenix’s RGX-019 program at the 2019 American Association for Cancer Research Annual Meeting.
-
BioSpace Movers and Shakers for Dec. 3
12/3/2018
Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more. -
Rgenix Appoints Serial Entrepreneur and Senior Executive Peter Van Vlasselaer to Board of Directors
11/27/2018
Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, today announced the appointment of Peter Van Vlasselaer, Ph.D., to its Board of Directors.
-
Rgenix Treats First Patient in Phase 1 Trial of RGX-202
10/31/2018
Rgenix, Inc. today announced it has treated the first patient in a Phase 1 a/b study of RGX-202.
-
Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs
10/9/2018
Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced that it has raised $40 million in a Series C financing in support of further development of the company’s clinical and pre-clinical oncology programs
-
Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting
6/4/2018
RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix continues Phase Ia/b trial with a RGX-104 monotherapy expansion cohort and dose escalation/ expansion cohorts of RGX-104 in combination with nivolumab.
-
Rgenix to Present Data on RGX-104 Clinical Activity at 2018 ASCO Annual Meeting
5/31/2018
Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it will present its abstract on RGX-104’s pharmacodynamic and clinical activity at the 2018 Annual Meeting of the American Society of Clinical Oncology. The meeting will take place in Chicago from June 1 through June 5.
-
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
-
Rgenix Presents Pre-Clinical Data on RGX-202 at the 2018 AACR Annual Meeting
4/18/2018
Pre-clinical data indicates RGX-202 suppresses cancer growth in colon and pancreatic cancer models Rgenix plans to initiate a clinical study of RGX-202 in patients with advanced gastrointestinal malignancies
-
Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity
1/12/2018
Rgenix announced today the publication of clinical and pre-clinical results by research collaborators at Rgenix and The Rockefeller University.
-
Rgenix Appoints Chief Medical Officer
4/28/2017